INCB8696
Posted: Sat Jan 27, 2007 12:01 pm
Not sure if this was posted before
Encouraging Early Study Results for Experimental CCR5 Antagonist INCB9471
At the JPMorgan Healthcare Conference earlier this month, Incyte Corporation announced promising preliminary data from a study of its investigational CCR5 antagonist candidate, INCB9471. The company also presented highlights of its ongoing drug development program, including agents to treat diabetes and cancer.
The following are edited excerpts from the company's January 8, 2007 press release:
New Incyte CCR5 Antagonist 14-Day Study Results
"WILMINGTON, Del. -- (BUSINESS WIRE) -- Jan 8, 2007 -- Incyte Corporation (Nasdaq: INCY) will announce today at the 25th Annual JPMorgan Healthcare Conference positive preliminary results from a Phase IIa placebo-controlled trial designed to evaluate the anti-viral effects and safety of INCB9471, Incyte's lead CCR5 antagonist that is being developed as a once-a-day oral treatment for patients with human immunodeficiency virus (HIV) infections."
"In the first 7 treated patients the compound was well tolerated over the 14-day trial period with a 1.7 log10 viral load drop at Day 14. Consistent with the compound's long half-life of 60 hours, viral replication continued to be suppressed after the last dose with a nadir in viral load reduction of 2.1 log10 seen at Day 20."
Incyte also announced:
• The initiation of a Phase I trial for a follow-on CCR5 antagonist, INCB15050, a potential once-a-day therapy for use in HIV-infected patients. This study is expected to be completed in the first quarter of this year.
• The filing of an Investigational New Drug Application (IND) for its lead CCR2 antagonist, INCB8696, which Incyte intends to develop first as an oral treatment for multiple sclerosis. Incyte may also pursue a second indication, lupus nephritis, and potentially other autoimmune nephritides. The Phase I trial is expected to initiate in the first quarter of this year.
• The announcement of several new programs in inflammation and oncology involving oral inhibitors of the janus-associated kinases (JAKs). There are four JAK enzymes, JAK1, JAK2, JAK3 and TKY2, which are an essential part of the intracellular signaling mechanisms used by a number of cytokines and growth factors. Incyte has identified a range of potent, moderately selective, oral JAK2 inhibitors from multiple chemical scaffolds. A number of these compounds are expected to enter clinical trials beginning in the first quarter of this year.
During 2007, the company plans to present final efficacy and safety data from the Phase IIa trial of INCB9471, complete the required drug interaction studies, and initiate a Phase IIb clinical study. It also hopes to complete the Phase I trial of INCB15050 and determine whether to proceed with further development.
01/26/07
Source
Incyte Corporation (Business Wire). Incyte to Report Positive Preliminary Clinical Results from HIV and Diabetes Programs and Highlight Progress in Several Drug Development Programs at the 25th JP Morgan Healthcare Conference. Press release. January 8, 2007.
Encouraging Early Study Results for Experimental CCR5 Antagonist INCB9471
At the JPMorgan Healthcare Conference earlier this month, Incyte Corporation announced promising preliminary data from a study of its investigational CCR5 antagonist candidate, INCB9471. The company also presented highlights of its ongoing drug development program, including agents to treat diabetes and cancer.
The following are edited excerpts from the company's January 8, 2007 press release:
New Incyte CCR5 Antagonist 14-Day Study Results
"WILMINGTON, Del. -- (BUSINESS WIRE) -- Jan 8, 2007 -- Incyte Corporation (Nasdaq: INCY) will announce today at the 25th Annual JPMorgan Healthcare Conference positive preliminary results from a Phase IIa placebo-controlled trial designed to evaluate the anti-viral effects and safety of INCB9471, Incyte's lead CCR5 antagonist that is being developed as a once-a-day oral treatment for patients with human immunodeficiency virus (HIV) infections."
"In the first 7 treated patients the compound was well tolerated over the 14-day trial period with a 1.7 log10 viral load drop at Day 14. Consistent with the compound's long half-life of 60 hours, viral replication continued to be suppressed after the last dose with a nadir in viral load reduction of 2.1 log10 seen at Day 20."
Incyte also announced:
• The initiation of a Phase I trial for a follow-on CCR5 antagonist, INCB15050, a potential once-a-day therapy for use in HIV-infected patients. This study is expected to be completed in the first quarter of this year.
• The filing of an Investigational New Drug Application (IND) for its lead CCR2 antagonist, INCB8696, which Incyte intends to develop first as an oral treatment for multiple sclerosis. Incyte may also pursue a second indication, lupus nephritis, and potentially other autoimmune nephritides. The Phase I trial is expected to initiate in the first quarter of this year.
• The announcement of several new programs in inflammation and oncology involving oral inhibitors of the janus-associated kinases (JAKs). There are four JAK enzymes, JAK1, JAK2, JAK3 and TKY2, which are an essential part of the intracellular signaling mechanisms used by a number of cytokines and growth factors. Incyte has identified a range of potent, moderately selective, oral JAK2 inhibitors from multiple chemical scaffolds. A number of these compounds are expected to enter clinical trials beginning in the first quarter of this year.
During 2007, the company plans to present final efficacy and safety data from the Phase IIa trial of INCB9471, complete the required drug interaction studies, and initiate a Phase IIb clinical study. It also hopes to complete the Phase I trial of INCB15050 and determine whether to proceed with further development.
01/26/07
Source
Incyte Corporation (Business Wire). Incyte to Report Positive Preliminary Clinical Results from HIV and Diabetes Programs and Highlight Progress in Several Drug Development Programs at the 25th JP Morgan Healthcare Conference. Press release. January 8, 2007.